ESC Premium Access

Ertugliflozin – A newly emerging SGLT2 inhibitor for patients with type 2 diabetes.

Topic: Cardiovascular Disease in Special Populations
Sponsored by MSD

Congress Presentation

About the speaker

Doctor Samuel Dagogo-Jack

Memphis (United States of America)
3 presentations
0 follower

6 more presentations in this session

Welcome and opening remarks.

Speaker: Professor D. McGuire (Dallas, US)

Thumbnail

Diabetes takes a center stage in overall risk for patients with cardiovascular disease .

Speaker: Doctor A. Gitt (Ludwigshafen, DE)

Thumbnail

SGLT2 Inhibitors: diabetes or cardiovascular drugs?

Speaker: Professor L. Leiter (Toronto, CA)

Thumbnail

Questions & Answers.

Speaker: Professor D. McGuire (Dallas, US) Doctor S. Dagogo-Jack (Memphis, US) Doctor A. Gitt (Ludwigshafen, DE) Professor L. Leiter (Toronto, CA)

Thumbnail

Envisioning the future of SGLT2 inhibitors in the treatment of patients with diabetes and cardiovascular disease: a roundtable discussion.

Speaker: Professor L. Leiter (Toronto, CA) Doctor A. Gitt (Ludwigshafen, DE) Professor D. McGuire (Dallas, US) Doctor S. Dagogo-Jack (Memphis, US)

Thumbnail

Access the full session

Five things cardiologists should know about diabetes

Speakers: Doctor S. Dagogo-Jack, Professor D. McGuire, Doctor A. Gitt, Professor L. Leiter, Professor D. McGuire...
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb